FR2562422B1 - Compositions pharmaceutiques a action anti-anoxique et metabolique cerebrale - Google Patents

Compositions pharmaceutiques a action anti-anoxique et metabolique cerebrale

Info

Publication number
FR2562422B1
FR2562422B1 FR858505338A FR8505338A FR2562422B1 FR 2562422 B1 FR2562422 B1 FR 2562422B1 FR 858505338 A FR858505338 A FR 858505338A FR 8505338 A FR8505338 A FR 8505338A FR 2562422 B1 FR2562422 B1 FR 2562422B1
Authority
FR
France
Prior art keywords
anoxic
pharmaceutical compositions
metabolic action
cerebral metabolic
cerebral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR858505338A
Other languages
English (en)
French (fr)
Other versions
FR2562422A1 (fr
Inventor
Alberto Bertelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seuref AG
Original Assignee
Seuref AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seuref AG filed Critical Seuref AG
Publication of FR2562422A1 publication Critical patent/FR2562422A1/fr
Application granted granted Critical
Publication of FR2562422B1 publication Critical patent/FR2562422B1/fr
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR858505338A 1984-04-09 1985-04-09 Compositions pharmaceutiques a action anti-anoxique et metabolique cerebrale Expired FR2562422B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1774/84A CH661438A5 (it) 1984-04-09 1984-04-09 Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.

Publications (2)

Publication Number Publication Date
FR2562422A1 FR2562422A1 (fr) 1985-10-11
FR2562422B1 true FR2562422B1 (fr) 1989-03-31

Family

ID=4218293

Family Applications (1)

Application Number Title Priority Date Filing Date
FR858505338A Expired FR2562422B1 (fr) 1984-04-09 1985-04-09 Compositions pharmaceutiques a action anti-anoxique et metabolique cerebrale

Country Status (7)

Country Link
US (1) US4684520A (ref)
JP (1) JPS6133118A (ref)
CH (1) CH661438A5 (ref)
DE (1) DE3417857C2 (ref)
FR (1) FR2562422B1 (ref)
GB (1) GB2157171B (ref)
IT (1) IT1201412B (ref)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661443A5 (en) * 1984-11-22 1987-07-31 Seuref Ag Pharmaceutical compositions having metabolic activity
JPH01305032A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 機能後退性消耗疾患治療予防剤及び飲食、し好物
JPH01305033A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 循環改善剤及び循環改善機能性食品並びにし好品
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
US6461593B1 (en) * 1992-02-19 2002-10-08 Biomedical And Clinical Research Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease
WO1994015595A1 (en) * 1993-01-06 1994-07-21 Jemo-Pharm A/S Medium comprising a pharmacological/biological active substance
US6312703B1 (en) 1998-02-06 2001-11-06 Lecigel, Llc Compressed lecithin preparations
US20030040505A1 (en) * 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6441050B1 (en) * 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
KR100612398B1 (ko) * 2000-11-14 2006-08-16 바이탈 헬스 사이언시즈 피티와이 리미티드 포스페이트 유도체의 착체
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
AU2002317053B2 (en) * 2001-07-27 2004-08-05 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
AUPR684801A0 (en) * 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
BR0215102A (pt) * 2001-12-13 2004-11-03 Vital Health Sciences Pty Ltd Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação
JP2003261456A (ja) * 2002-03-08 2003-09-16 Howaizu:Kk 脳の老化予防剤
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
BRPI0406484A (pt) * 2003-01-17 2005-12-06 Vital Health Sciences Pty Ltd Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US8252322B2 (en) * 2003-06-03 2012-08-28 Corn Products Development, Inc. Delivery system with increased bioavailability
TW200524541A (en) * 2003-11-17 2005-08-01 Cargill Inc Lecithin-containing granular compositions and methods of their preparation
US20060069157A1 (en) * 2004-02-19 2006-03-30 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as Huntington's disease, by sodium butyrate chemotherapy
CA2557354C (en) 2004-03-03 2013-05-07 Vital Health Sciences Pty Ltd. Alkaloid formulations
RU2448977C2 (ru) * 2004-09-16 2012-04-27 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Обладающий способностью облегчать по меньшей мере один симптом воспалительного состояния пептид, содержащая его фармацевтическая композиция и способ лечения атеросклероза с их помощью
US7901675B2 (en) * 2004-10-13 2011-03-08 U.S. Department Of Veterans Affairs Method of using coenzyme Q10 to treat Huntington's disease
US7579319B2 (en) 2004-12-06 2009-08-25 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US20060135612A1 (en) * 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
WO2006092024A1 (en) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Compounds having anti-cancer properties
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP1890715A4 (en) * 2005-04-29 2009-10-28 Univ California PEPTIDES AND PEPTIDE MIMETICS FOR TREATMENT BY INFLAMMATORY REACTION OF CHARACTERIZED PATHOLOGIES
MX2007015949A (es) * 2005-06-17 2008-03-07 Vital Health Sciences Pty Ltd Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos.
DE102005056558B4 (de) * 2005-11-25 2009-04-30 Gisela Susilo Kombinationspräparate enthaltend physiologische Zellmembran-Bestandteile
WO2007070981A1 (en) * 2005-12-23 2007-06-28 Vital Health Sciences Pty Ltd Compounds having cytokine modulating properties
GB0603975D0 (en) * 2006-03-01 2006-04-05 Etren Methods and agents for reducing oxidative stress
CA2649315A1 (en) * 2006-04-10 2007-10-25 Mitsubishi Gas Chemical Company, Inc. Brain function-improving agent, and functional food containing the improving agent
US20100061969A1 (en) * 2006-11-22 2010-03-11 Asahi Kasei Pharma Corporation Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic
EP2195331B1 (en) 2007-08-28 2013-11-20 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
JP5806287B2 (ja) 2010-03-30 2015-11-10 フォスファジェニクス リミティド 経皮送達パッチ
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
US12264593B1 (en) 2023-11-09 2025-04-01 Pratt & Whitney Canada Corp. Damped bladed rotor for gas turbine engine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5938202B2 (ja) * 1976-03-05 1984-09-14 エーザイ株式会社 難聴治療剤
JPS5356315A (en) * 1976-11-01 1978-05-22 Eisai Co Ltd Emulsified solution of fat soluble drugs
US4221784A (en) * 1979-04-05 1980-09-09 Massachusetts Institute Of Technology Process and composition for treating disorders by administering lecithin
FR2472384A1 (fr) * 1979-12-27 1981-07-03 Sederma Sa Utilisation en cosmetologie de complexes naturels constitues d'ubiquinones et de phospholipides
JPS5742616A (en) * 1980-08-27 1982-03-10 Furointo Sangyo Kk Ubiquinone pharmaceutical having improved absorption
JPS5775916A (en) * 1980-10-29 1982-05-12 Nippon Chemiphar Co Ltd Coenzyme q pharmaceutical and its preparation
JPS57142911A (en) * 1981-02-28 1982-09-03 Furointo Sangyo Kk Absorption-improving agent
JPS58113127A (ja) * 1981-12-28 1983-07-05 Ajinomoto Co Inc ユビデカレノン含有水性液
CH649917A5 (en) * 1982-03-19 1985-06-28 Italfarmaco Sa Pharmaceutical formulations containing the coenzyme Q(10) suitable for topical administration
JPS58201711A (ja) * 1982-05-19 1983-11-24 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体

Also Published As

Publication number Publication date
GB8508452D0 (en) 1985-05-09
JPH0530813B2 (ref) 1993-05-11
JPS6133118A (ja) 1986-02-17
IT1201412B (it) 1989-02-02
DE3417857C2 (de) 1997-04-24
DE3417857A1 (de) 1985-10-17
GB2157171B (en) 1988-07-06
US4684520A (en) 1987-08-04
GB2157171A (en) 1985-10-23
CH661438A5 (it) 1987-07-31
FR2562422A1 (fr) 1985-10-11
IT8520271A0 (it) 1985-04-05

Similar Documents

Publication Publication Date Title
IT1201412B (it) Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale
BR1100036A (pt) Composto e composição farmacêutica
FR2547727B1 (fr) Compositions pharmaceutiques
SE8801813L (sv) Pharmaceutical composition
FR2636532B1 (fr) Compositions pharmaceutiques
KR890004174U (ko) 겔화제를 지닌 흡수구조물 및 이들 구조물을 함유하는 흡수제품
IT8621358A1 (it) Composizione farmaceutica ad attività analgesica
KR870700608A (ko) 아미노-살리실산 유도체 및 제약 조성물
IT1209615B (it) Composizione farmaceutica
IT8621393A1 (it) Composizioni farmaceutiche ad azione vasodilatatrice ed antianossica
IT1187756B (it) Isoindolinil-alchil-piperazine ad attivita' farmaceutica
IT8149623A0 (it) Derivati encefalinici dotati di attivita' analgesica e composizioni farmaceutiche che li contengono
IT1214641B (it) Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.
IT1161213B (it) Composizioni farmaceutiche ad attivita' antineoplastica
EP0298706A3 (en) Glycans and their use as anti-viral agents
FR2580497B1 (fr) Compositions pharmaceutiques en comprimes
FR2566662B1 (fr) Association medicamenteuse utilisee en photochimiotherapie
IT1189308B (it) L'impiego in terapeutica d'un derivato dell'acetammide
BR8905729A (pt) Composicao e emprego
IT8448847A0 (it) Sostanze farmaceutiche e profilatti che antiadesivi contenenti un derivato benzilamminico ad attivita' secretolitica
FR2584294B1 (fr) Compositions pharmaceutiques a visee cytotrophique
IT1173445B (it) Agenti ad attivita' antibroncospastica e composizioni farmaceutiche che li contengono
FR2571058B1 (fr) Nouveau film composite et sa preparation
IT8547704A1 (it) Diazepinoindoli loro preparazione e loro impiego come medicamenti
IT1096582B (it) Dieteri idrochinonici aventi attivita' ormonica giovanile e acaricida

Legal Events

Date Code Title Description
TP Transmission of property